Investigations into the haemolytic effects of dapsone therapy in leprosy patients.
Investigations into the haemolytic effects of dapsone therapy were carried out in forty four leprosy patients admitted to the Sacred Heart Leprosy Centre, Kumbakonam. They received weight based dapsone dosages varying from 1.3-3.3 mg/kg body weight. Blood levels and urinary Dapsone/creatinine ratio were assessed at 1 day, 7 days and 30 days of Dapsone treatment. At the same points of time, haematological observations were also carried out. Serum bilirubin as well as blood mathaemoglobin were also examined. The findings showed a reduction in Hb levels at 30 days observation in a good proportion of cases on 100 mg. In one case (child) weighing 15 kg and receiving 50 mg dapsone increased mathaemoglobin was observed. It is suggested that dapsone dosage be regulated to body weight and preferably not to exceed 1.5 mg/kg body weight.
Balakrishnan
S
S
Dept. of Biochemistry, Sacred Heart Leprosy Centre, Tamil Nadu.
Karthikeyan
S
S
Ramu
G
G
D000293:Adolescent; D000328:Adult; D001663:Bilirubin / Q000097:blood; D001835:Body Weight; D002648:Child; D003622:Dapsone / Q000008:administration & dosage / Q000009:adverse effects* / Q000378:metabolism; D004334:Drug Administration Schedule; D004906:Erythrocyte Count / Q000187:drug effects; D005260:Female; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D015439:Leprosy, Borderline / Q000188:drug therapy / Q000378:metabolism*; D015440:Leprosy, Lepromatous / Q000188:drug therapy / Q000378:metabolism*; D015441:Leprosy, Tuberculoid / Q000188:drug therapy / Q000378:metabolism*; D008297:Male
D003622:Dapsone; D001663:Bilirubin